Bangladesh - English - DGDA (Directorate General of Drug Administration)

mst pharma and healthcare ltd. - ascorbic acid + biotin + boron + calcium + chromium + copper + cyanocobalamin + elemental iron + folic acid + iodine + lutein + magnesium + manganese + molybdenum + niacin + nickel + pantothenic acid + phosphorous + pottassium + pyridoxine hydrochloride + riboflavin + selenium + silicon + tin + vanadium + vitamin a + vitamin b1 + vitamin d3 + vitamin e + vitamin k + zinc - tablet - 60 mg + 30 mcg + 150 mcg + 162 mg + 120 mcg + 2 mg + 6 mcg + 18 mg + 400 mcg + 150 mcg + 250 mcg + 100 mg + 2 mg + 75 mcg + 20 mg + 5 mcg + 10 mg + 109 mg + 80 mg + 2 mg + 1.7 mg + 20 mcg + 2 mg + 10 mcg + 10 mcg + 5000 iu + 1.5 mg + 400 iu + 30 iu + 25 mcg + 15 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

mst pharma and healthcare ltd. - ascorbic acid + biotin + calcium + choline bitartrate + chromium + cyanocobalamin + inositol + iodine + magnesium + manganese + pantothenic acid + para-amino-benzoic acid + pottassium + riboflavin + selenium + vitamin a + vitamin b1 + vitamin d3 + vitamin e + zinc - syrup - 1350 mg + 650 mcg + 550 mg + 200 mg + 70 mcg + 60 mcg + 200 mg + 500 mcg + 150 mg + 15 mg + 70 mg + 10 mg + 140 mg + 20 mg + 350 mcg + 17000 iu + 20 mg + 2750 iu + 200 iu + 50 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - glycopyrronium bromide - oral tablet - 1mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - glycopyrronium bromide - oral tablet - 2mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - enoxaparin sodium 100 mg/ml;   - solution for injection - 100 mg/ml - active: enoxaparin sodium 100 mg/ml   excipient: water for injection - prophylaxis of venous thromboembolism in general medical patients bedridden due to acute illnesses including acute heart failure, respiratory failure, severe infections, rheumatic disease. prophylaxis of venous thromboembolic disease, in particular those which may be associated with orthopaedic, general, major colorectal or cancer surgery.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - enoxaparin sodium 150 mg/ml;   - solution for injection - 150 mg/ml - active: enoxaparin sodium 150 mg/ml   excipient: water for injection - - treatment of venous thromboembolic disease. - prevention of thrombus formation in the extra-corporeal circulation during haemodialysis.

European Union - English - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: silicon dioxide; magnesium stearate; sodium starch glycollate type a; hypromellose phthalate; gelatin; brilliant blue fcf; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - itraconazole, quantity: 50 mg - capsule - excipient ingredients: sodium starch glycollate type a; titanium dioxide; brilliant blue fcf; hypromellose phthalate; silicon dioxide; magnesium stearate; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - superficial mycoses: lozanoc is indicated, if external treatment is not effective or not appropriate, for the treatment of the following fungal infections: dermatomycoses (e.g. tinea corporis, tinea cruris, tinea pedis, tinea manus, tinea unguium) and pityriasis versicolor. systemic mycoses: lozanoc is indicated for the treatment of systemic mycoses, such as candidiasis, aspergillosis, and histoplasmosis. consideration should be given to official guidance on the appropriate use of antimycotic agents, and to the discussion of the pharmacodynamic properties (see pharmacology).

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - morphine sulfate pentahydrate, quantity: 10 mg - capsule, modified release - excipient ingredients: purified talc; purified water; maize starch; gelatin; sucrose; methacrylic acid copolymer; ethylcellulose; hypromellose; macrogol 6000; diethyl phthalate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - management of severe pain kapanol 10, 20, 50 and 100 mg capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. kapanol is not indicated for use in chronic non-cancer pain other than in exceptional circumstances. kapanol is not indicated as an as-needed (prn) analgesia.,symptom reduction of chronic breathlessness kapanol 10 and 20 mg capsules are indicated for the symptomatic reduction of chronic breathlessness in the palliative care of patients with distressing breathlessness due to severe copd, cardiac failure, malignancy or other cause. kapanol should only be used after treatments for the underlying cause(s) of the breathlessness have been optimised and nonpharmacological treatments are not effective. treatment with kapanol in this setting should only be initiated by a specialist knowledgeable in its use.